| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.2 | 4e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.19 | 7e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.17 | 0.003 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.007 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.092 | 0.007 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.098 | 0.007 |